A New Light on Bladder Cancer Management: Integrating Laser Ablation into Endourological Care Pathways. Comment on Katz-Summercorn et al. Evolution of the Bladder Cancer Pathway in a Secondary Care Unit Incorporating Transurethral Laser Ablation and ‘Bladder Cancer Surgery Planning Meetings’. Soc. Int. Urol. J. 2026, 7, 17

In this issue, Alexander Charles Katz-Summercorn et al. have explored the safety and oncological efficacy of an alternate endourological approach while dealing with Non Muscle invasive Bladder cancer [1]. Non-muscle-invasive bladder cancer (NMIBC) is the 7th most common cancer worldwide in men and the 17th most common cancer worldwide in women. Approximately 75% of newly diagnosed urinary bladder cancer (UBCs) are non-invasive [2]. Most new bladder cancer diagnoses require repeated treatments and long-term follow-up, placing a significant ongoing burden on healthcare services [3]. Transurethral resection of bladder tumour (TURBT) under general anaesthesia continues to be the gold standard method for managing bladder tumours [4]. In routine clinical practice, limited theatre availability, delays in pre-operative assessment, and an ageing patient population often delay timely treatment, prompting clinicians to consider alternative approaches.

This study describes the use of transurethral laser ablation (TULA) alongside Bladder Cancer Surgery Planning Meetings (BSPM) in a secondary-care unit. TULA was performed with a flexible cystoscope and ‘cold cup’ biopsies with ablation and haemostasis using a 1470 nm Diode laser at 4 watts and 400 µm laser fibre. A retrospective study was performed on 95 patients who underwent a TULA procedure between August 2023 and November 2024 before the audit and then September 2025 over a 25-month-period. Small, visually accessible lesions, recurrent and low-grade in appearance on cystoscopy assessment, were included after multidisciplinary team (MDT) discussion.

The focus is not on replacing TURBT, but on adapting the pathway to improve access to treatment without compromising patient safety. There is a gradual shift in procedures performed under general anaesthesia to local anaesthesia. This is of particular importance in patients who have comorbidities with American Society of Anaesthesiologists (ASA) III, waiting for anaesthetic fitness, which can lead to prolonged waiting times and delays in treatment.

Adequate detrusor muscle sampling remains central in the case of bladder tumour stratification. Detrusor muscle was detected in 66.3% of specimens with flexible cold cup biopsy, comparable to the British Association of Urological Surgeons standard for TURBT at 70% [5], demonstrating staging without the need for TURBT under general anaesthesia (GA). The complication rate was 1.1% while previous studies reported 1–5% compared to 6% in TURBT [6,7], which makes it safer to perform as an outpatient procedure, even for patients on antiplatelet therapy without bridging or stopping drugs.

Long-term recurrence-free survival rates following TULA are also comparable to TURBT, with studies reporting 5-year recurrence-free survival of 29–32% for intermediate- and high-risk NMIBC [7]. Patient-reported outcomes favour TULA over TURBT, supporting TULA as a safe adjunct to standard treatment.

A major strength of this study is the use of BSPM, which helps identify patients suitable for TULA and emphasises prior multidisciplinary discussion. Since TULA is carried out under local anaesthesia in an outpatient setting, it lessens the demand on operating theatre time, burden and resources, ultimately lowering costs.

One has to be mindful of the limitations of the study before incorporating this pathway. The retrospective design and relatively short follow-up period limit conclusions regarding long-term outcomes as tumour recurrence and progression. Selection bias is unavoidable, as patients are chosen after flexible cystoscopy. The success is multifactorial, depending on access to laser equipment, operator experience, and robust follow-up arrangements, which may limit its clinical utility. Ongoing surveillance and a low threshold for conventional resection remain necessary.

This study demonstrates that TULA can be incorporated into a bladder cancer pathway when used in carefully selected patients and supported by structured multidisciplinary decision-making. With clear protocols, monitoring and longer-term follow-up data, this pathway has the potential to improve efficiency, reduce waiting times, and maintain patient safety in secondary-care settings. Deescalation strategies are being increasingly explored across oncology care pathways and this attempt may also align in the same direction. The present study should encourage multicentric studies across Urology community to refine the adaptability of this approach.